Revelation Biosciences, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants, generating approximately $9.6 million in gross proceeds. These warrants, originally issued by the company on May 29, 2025, allowed for the purchase of up to 4,355,000 shares of common stock. The exercise price for these warrants was $2.20 per share.
The shares of common stock issuable upon the exercise of these existing warrants are registered pursuant to an effective registration statement on Form S-1. This capital infusion provides Revelation Biosciences with substantial additional resources. The funds will support the company's ongoing clinical development programs and general corporate purposes.
This financing event follows closely on the heels of the company's announcement of groundbreaking top-line results from its Phase 1b PRIME clinical study. The ability to raise significant capital after positive clinical data is a strong indicator of investor confidence in the Gemini platform and its potential. This funding is critical for advancing the company's pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.